This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Diovan (valsartan) and Amlodipine fixed-dosed combination; Copalia; Dafiro; Imprida; VAA489
Description: Diovan/Amlodipine is a fixed-dose combination of Diovan (Valsartan) with amlodipine. Diovan is a nonpeptide, orally active, and specific angiotensin II antagonist (angiotensin receptor blockers or ARBs). It blocks the ability of angiotensin II to constrict or squeeze arteries and veins, thereby reducing blood pressure and reducing the pressure in the arteries that the heart must pump against. Amlodipine besylate is a long-acting calcium channel blocker (CCB) that dilates blood vessels.
This coformulation is the first to combine a CCB with an ARB, offering a once-daily treatment with a dual mechanism of action that combines the benefits of both drugs in one pill.
Ipsen and Novartis
In January 2009, Ipsen announced that it signedan agreement with Novartis for the co-promotion in France of Exforge.
In May 2012, Ipsen announced that it had terminated its agreement with Novartis for the co-promotion of Exforge in France. Ipsen will receive a contractual cash exit fee payment of EUR4 million from Novartis.
UCB and Novartis
In August 2009, UCB and Novartis announced that they entered into a licensing agreement for cardiovascular and diabetes products in Germany. Under the agreement, UCB licensed in commercial rights for Dafiro (valsartan and amlodipine) and Dafiro HCT (valsartan, amlodipine and HCT).
Partners: UCB SA
Additional information available to subscribers only: